Company Profile
Aquestive Therapeutics Stock Price, News & Analysis
Company overview
Business overview
Aquestive Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Aquestive Therapeutics is followed within the biopharmaceutical universe for its exposure to pipeline and commercialization catalysts.
Business Model Characteristics
Aquestive Therapeutics follows a pipeline-led model where clinical readouts, filing updates, and program expansion determine how the market underwrites the story.
Position Within the Biotechnology Landscape
Compared with more mature healthcare names, Aquestive Therapeutics sits on the development side of the biotech landscape, where catalyst timing can reprice the stock quickly.
Why the stock is moving
AQST is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Future catalysts
Aquestive’s catalysts are Anaphylm, Libervant execution, and any regulatory or launch update that broadens the commercial story. The company’s stock moves most when the product path gets clearer.
Recent news
The five most recent feed items are shown below in reverse chronological order.
- 01
Aquestive Therapeutics Appoints Internationally Recognized Allergist Dr. Matthew Greenhawt as Chief Medical Officer
Source: Aquestive Therapeutics
- 02
- 03
Aquestive Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference
Source: Aquestive Therapeutics
- 04
- 05
Aquestive Therapeutics to Participate in Upcoming March Investor Conferences
Source: Aquestive Therapeutics
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.